Last reviewed · How we verify

Desloratadin — Competitive Intelligence Brief

Desloratadin (Desloratadin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed 5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1 Other Small molecule Live · refreshed every 30 min

Target snapshot

Desloratadin (Desloratadin) — Max Zeller Soehne AG.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Desloratadin TARGET Desloratadin Max Zeller Soehne AG marketed 5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1
Clarinex desloratadine Generic (originally Schering-Plough/MSD) marketed Histamine-1 Receptor Antagonist [EPC] 5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1 2001-12-21

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Desloratadin — Competitive Intelligence Brief. https://druglandscape.com/ci/desloratadin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: